VCNX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 geg. 2024 @ 23:00):

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs...

Stats
Dzisiejszy wolumen	10 063.00
Średni wolumen	14 287.00
Kapitalizacja rynkowa	8.55M
EPS	$0 ( 2024-04-02 )
Następna data zysków	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.140
ATR14	$0.179 (2.98%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Friedberg Albert	Buy	282	Common Stock
2024-03-28	Zauderer Maurice	Buy	38 610	Common Stock
2024-03-28	Zauderer Maurice	Buy	38 610	Warrant (Right to Buy)
2024-03-28	Friedberg Albert	Buy	102 960	Common Stock
2024-03-28	Friedberg Albert	Buy	102 960	Warrant (Right to Buy)

INSIDER POWER
99.87
Last 100 transactions
Buy: 40 266 892 \| Sell: 9 809 782

Vaccinex Inc Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Vaccinex Inc Finanse

Annual	2023
Przychody:	$570 000
Zysk brutto:	$451 000 (79.12 %)
EPS:	$-43.68

FY	2023
Przychody:	$570 000
Zysk brutto:	$451 000 (79.12 %)
EPS:	$-43.68

FY	2022
Przychody:	$100 000
Zysk brutto:	$-107 000 (-107.00 %)
EPS:	$-97.59

FY	2021
Przychody:	$900 000
Zysk brutto:	$900 000 (100.00 %)
EPS:	$-1.191

Financial Reports:

No articles found.

Vaccinex Inc

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.